C

Capital Area Research | Camp Hill, PA

Research site
(Unclaimed)
Location
875 Poplar Church Road, Suite 330, Camp Hill, Pennsylvania, United States of America
Site insights

Top conditions

Heart Failure (8 trials)

Type 2 Diabetes Mellitus (5 trials)

Obesity (5 trials)

Diabetes Mellitus (5 trials)

Overweight (5 trials)

Top treatments

Tirzepatide
LY3298176
LY3502970
Apixaban
Finerenone
LY3819469
REGN1500
Evinacumab
Aldosterone
ARO-ANG3

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

15 of 41
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]

The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts abou...

Active, not recruiting
Lipoprotein Disorder
Drug: LY3819469
Drug: Placebo

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling
Atrial Fibrillation
Drug: Placebo
Drug: Apixaban Placebo

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide
Locations recently updated

The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejec...

Active, not recruiting
Heart Failure With Preserved Ejection Fraction (HFpEF)
Obesity
Other: Placebo
Drug: Tirzepatide

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Other: Placebo

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to...

Enrolling
COVID-19
Influenza
Biological: Placebo
Biological: Influenza and COVID-19 Combination B
Locations recently updated

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo

To demonstrate the safety and efficacy of the SurVeil Drug-Coated Balloon (DCB) for treatment of subjects with symptomatic peripheral artery disease...

Active, not recruiting
Peripheral Vascular Disease
Femoropopliteal Artery Occlusion
Device: Surmodics SurVeil DCB
Device: Medtronic IN.PACT Admiral DCB

The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in participants with mixed dyslipidemia. Participants will initially r...

Active, not recruiting
Mixed Dyslipidemia
Drug: Placebo
Drug: ARO-ANG3

The study is a placebo-controlled, double-blind, randomized, phase 3 study in participants with heterozygous familial hypercholesterolemia (HeFH) and...

Enrolling
Dyslipidemias
Hypercholesterolemia
Other: Combination Therapy placebo
Other: Ezetimibe Placebo

The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiov...

Active, not recruiting
Heart Failure
Other: Placebo
Drug: Finerenone (BAY94-8862)

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Active, not recruiting
Lower Respiratory Tract Illness
Biological: Placebo
Biological: RSVpreF

Trial sponsors

Lilly logo

Lilly (10 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems